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However, other recent clinical studies also show neutral effects (11) (12) (13) (14) (15) , and better understanding of the mechanisms of rIPC in humans may lead to maximization of its benefits. The signaling pathway from the trigger limb to target organs is poorly defined, but involves release of circulating factor(s) (16) (17) (18) (19) (20) (21) (22) (23) and neural pathways (19, (24) (25) (26) .
In preclinical animal models, adenosine antagonists inhibit cardiac rIPC induced by renal and mesenteric ischemia (27, 28) . Furthermore, femoral arterial (but not femoral vein) adenosine infusion preconditioned rat hearts and was inhibited by femoral nerve transection. In a rabbit model, femoral artery (but not femoral vein) infusion of adenosine released humoral cardioprotective factor(s) into the circulation, which reduced infarct size when transferred to a naive Langendorff heart (19) . However, a more recent porcine study suggests that adenosine is not involved in rIPC (29) . The role of the adenosine pathway in human rIPC remains unknown but clearly warrants further investigation.
The aims of this study were to address: 1) whether adenosine receptor activation is involved in human endothelial rIPC-induced by limb ischemia;
2) whether adenosine receptor activation is involved in the "trigger" or "target" phases of rIPC; 3) its effects on release of circulating cardioprotective factor(s); and 4) whether arterial infusion of adenosine liberates release of a circulating cardioprotective factor(s) in humans. were assessed before and after combined rIPC and IR. All recordings and analysis were made using LabChart v.6 (AD Instruments, Chalgrove, United Kingdom). After 20-min stabilization, isolated hearts were perfused for 30 min using dialysate, washed out for 5 min, and then subjected to 30 min of no-flow global ischemia followed by 60 min of reperfusion. The left ventricular (LV) developed pressure was calculated as the difference between the systolic and end-diastolic LV pressures. After freezing, the heart was then sliced into 1-mm slices from the apex to the base, and slices were incubated in 1% 2,3,5-triphenyltetrazolium chloride (pH 7.4) (Sigma-Aldrich) at 37 C for 15 min.
All slices were then scanned on a flat-bed digital scanner and weighed. Infarct size was determined by semiautomated computer planimetry (Image Pro Analyzer v7.0, Bethesda, Maryland). Because this was a model of global ischemia, the whole heart acts as the "area at risk", and infarct size is presented as a percentage of whole-heart mass. reperfusion. In addition, venous blood was drawn for producing dialysate and testing for the presence of a circulating cardioprotective factor(s) before and after rIPC.
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Adenosine in rIPC Figure 2 ). Baseline caffeine measurements confirmed that participants had adhered to caffeine avoidance. Caffeine levels increased appropriately, confirmed correct group allocations after unblinding, and were comparable to previously described values using this protocol (1.7 mmol/l to 20.0 mmol/l in the caffeine group and 3.0 mmol/l to 2.2 mmol/l in the placebo group). The protocol was well tolerated by participants and was without sequelae.
C o n t r o l e x p e r i m e n t : e f f e c t o f c a f f e i n e o n F M D a n d I R . Five participants underwent control Values are mean AE SEM. There were no significant differences in between group demographic characteristics. Caffeine demonstrated a highly significant rise in the caffeine infusion group as expected (p < 0.0001 by paired t test).
BMI ¼ body mass index; HR ¼ heart rate; MAP ¼ mean arterial pressure.
FIGURE 2 Serum Caffeine and Hemodynamic Indices in Protocol 1
Serum caffeine levels and hemodynamic changes. An expected significant increase was seen in systemic caffeine levels following caffeine infusion from 1.7 AE 0.5 to 20.3 AE 1.2 (A) (p < 0.0001 by paired t test). This had no significant effect on the heart rate (B) or blood pressure (C) graph. Box and whiskers represent the median and 5th and 95th percentiles, respectively. Abbreviations as in Figure 1 . A total of 20 studies were conducted with 10 patients randomized to each group. Participant demographic characteristics are listed in Table 3 . showing that there is a significant reduction in MI, suggesting preserved release of circulating factor(s). Abbreviations as in Figure 1 . Importantly, we have identified a novel pathway that liberates circulating cardioprotective factor(s), which can be pharmacologically stimulated in humans.
In protocol 1, we delivered caffeine systemically and this inhibited the protective effect of rIPC. In protocol 2, we delivered the caffeine into the brachial artery to achieve inhibition of adenosine receptors in either the trigger or target limb. We demonstrate that adenosine receptor inhibition in the trigger limb blocks the induction of systemic rIPC and inhibits release of circulating cardioprotective factor(s).
However, rIPC is preserved when caffeine is delivered into the target organ, and release of the circulating factor(s) after rIPC is also maintained. For methodological reasons, we used FMD to assess endothelial responses of the contralateral arm when we infused into the trigger arm, because we did not deem it appropriate to cannulate both brachial arteries. We used venous occlusion plethysmography when we infused into the target tissue, because FMD cannot be practically performed in this situation due to the proximity of the ultrasound probe to the arterial cannula and its impingement upon it. Caffeine has been used to investigate pre-conditioning pathways in humans previously (33) .
Four nonhuman studies investigating kidney or intestinal ischemia have reported that adenosine receptor antagonists inhibit cardiac rIPC (27, (35) (36) (37) .
One study has shown no effect of adenosine antagonist on renal rIPC (38) . Values are mean AE SEM. In this crossover study, there were no significant changes seen in the 8 weeks between visits.
Abbreviations as in Table 1 . As with all studies using competitive inhibitors, it is possible that off-target effects of caffeine influence our results, but there are currently no available adenosine receptor subtype-specific antagonists for human use. It is also true that our model is specific to human endothelial rIPC rather than human cardiac rIPC, and although we term the liberated factor(s) cardioprotective, it has only been demonstrated to truly protect myocardium in experimental animal models, and its effect on human myocardium in vivo is unknown. However, further work is necessary in this regard.
It should also be noted that the volunteers in our studies in protocols 1 and 2 were young and free of chronic health problems, and so as such, were not representative of the more elderly individuals, with multiple comorbidities and on medications, who more typically present with coronary disease syndromes, and in whom this intervention is most relevant. Indeed, it may be that pre-conditioning in these 
